Floatz logo

FOSLINANIB

Neuroendocrine Tumors

TaiRx, Inc.Small moleculePhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

61 Active assets in the Neuroendocrine Tumors cohort.

Asset / SponsorPhaseRating
Bms-907351
Fox Chase Cancer Center
Phase 3BB
Eloxatin
ITM Solucin GmbH
Phase 3BB
Irinotecan
First Affiliated Hospital Xi'an Jiaotong University
Phase 4BB
FLUOROURACILUM
ITM Solucin GmbH
Phase 3BB
Pasireotide
RECORDATI GROUP
Phase 4BB

View all 50 →

Same molecule, other indications

FOSLINANIB is also rated in:

cancerDormant
CCC
Indicative ·
55 / 100
View asset →
pancreatic neuroendocrine tumorDormant
CCC
Indicative ·
53 / 100
View asset →
digestive system neuroendocrine neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →